NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

ADME毒性檢驗的全球市場

ADME-Toxicology Testing

出版商 Global Industry Analysts, Inc. 商品編碼 210377
出版日期 內容資訊 英文 405 Pages
商品交期: 最快1-2個工作天內
價格
ADME毒性檢驗的全球市場 ADME-Toxicology Testing
出版日期: 2021年04月01日內容資訊: 英文 405 Pages
簡介

本報告提供全球ADME毒性檢驗市場相關調查,提供您產業概要與市場趨勢,藥物研發的藥物開發趨勢,產品概要,各地區趨勢,企業簡介等彙整資料。

第1章 簡介,調查方法,產品定義

第2章 摘要整理

  • 今後預測
    • 氣勢漸增的ADME毒性實驗
    • ADME毒性檢驗為新藥物研發帶來的影響
    • 現在及未來分析
    • 即使歐美獨佔市場,亞太地區仍有成長氣勢
    • 成長領域in vivo技術產生變化,in vitro技術佔優勢
  • 產業概要
    • 醫藥品產業再度著重成本最佳化
    • 中國與印度:研究開發投資的中心地
    • ADME毒性化驗:概要
    • 早期in vitroADME毒性檢驗的簡介
    • 藥物研發及ADME分析的細胞化驗分析的興起
    • 藥物檢驗的細胞基HTS化驗主要類型
    • CRO的地位擴大
    • 藥物研發的外包和外包服務的種類
    • M&A:潮流
  • 市場趨勢
  • 藥物研發和藥物開發
    • 概要
    • 藥物研發和藥物開發
    • 標的鑑定
    • 標的驗證
    • 領導特定
    • 先導藥物最適化
    • 前臨床檢驗
    • 臨床實驗
    • 藥物研發技術
    • 篩檢的技術創新保證了藥物研發計劃的成功
  • 產品概要
    • ADME毒性:簡介
    • 吸收
    • 分佈
    • 代謝
    • 排泄
    • 毒性
    • ADME毒性分析
    • ADME毒性篩檢技術
    • ADME毒性參數
    • 細胞化驗分析
    • 幹細胞化驗
    • 小腸細胞化驗
    • 腎臟細胞化驗
  • 產品技術創新/引進
  • 近幾年的產業活動
  • 主要企業
    • ACEA Biosciences, Inc.
    • ADMEcell, Inc.
    • Agilent Technologies, Inc.
    • Albany Molecular Research, Inc.
    • Bayer Technology Services GmbH
    • Beckman Coulter, Inc.
    • BioreclamationIVT, LLC
    • Cambridge Cell Networks Ltd.
    • Cerep SA
    • CompuDrug International, Inc.
    • Cyprotex PLC.
    • CeeTox, Inc.
    • Dassault Systemes
    • Entelos, Inc.
    • Elsevier B.V.
    • Eurofins ADME BIOANALYSES SAS
    • Galapagos NV
    • Molecular Discovery Ltd.
    • MultiCASE, Inc.
    • Optivia Biotechnology
    • PerkinElmer, Inc.
    • Pharmaron, Inc.
    • Promega Corporation
    • Qualyst, Inc.
    • Simulations Plus, Inc.
    • Taconic Farms, Inc.
    • Takara Bio Europe AB
    • Tecan Group Ltd.
    • Thermo Fisher Scientific, Inc.
    • Xceleron, Inc.
  • 全球市場預測

第3章 市場

  • 美國
  • 加拿大
  • 日本
  • 歐洲
    • 法國
    • 德國
    • 義大利
    • 英國
  • 亞太地區
  • 其他各國

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: MCP-7635

Abstract:

Global ADME-Toxicology Testing Market to Reach $10.2 Billion by 2027

Amid the COVID-19 crisis, the global market for ADME-Toxicology Testing estimated at US$5.2 Billion in the year 2020, is projected to reach a revised size of US$10.2 Billion by 2027, growing at a CAGR of 10.1% over the analysis period 2020-2027. Cell Culture, one of the segments analyzed in the report, is projected to record a 11.7% CAGR and reach US$4.6 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the High Throughput segment is readjusted to a revised 8.1% CAGR for the next 7-year period.

The U.S. Market is Estimated at $1.4 Billion, While China is Forecast to Grow at 13.3% CAGR

The ADME-Toxicology Testing market in the U.S. is estimated at US$1.4 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$2.2 Billion by the year 2027 trailing a CAGR of 13.6% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 6.9% and 8.6% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 7.8% CAGR.

Molecular Imaging Segment to Record 9.8% CAGR

In the global Molecular Imaging segment, USA, Canada, Japan, China and Europe will drive the 9.1% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$860.6 Million in the year 2020 will reach a projected size of US$1.6 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$1.5 Billion by the year 2027, while Latin America will expand at a 11.2% CAGR through the analysis period.

Select Competitors (Total 69 Featured) -

  • ACEA Biosciences Inc.
  • ADMEcell Inc.
  • Agilent Technologies, Inc.
  • Albany Molecular Research Inc.
  • Beckman Coulter Inc.
  • CompuDrug International Inc.
  • Cyprotex PLC.
  • Dassault Systemes Biovia Corp.
  • Eurofins ADME BIOANALYSES SAS
  • Galapagos NV
  • Molecular Discovery Ltd.
  • MultiCASE Inc.
  • Optivia Biotechnology
  • PerkinElmer Inc.
  • Promega Corporation
  • Simulations Plus Inc.
  • Takara Bio Europe AB
  • Tecan Group Ltd.
  • Thermo Fischer Scientific Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • ADME-Tox Testing Gains Traction
    • Recent Market Activity
    • A Peek into the Impact of ADME-Tox Screening on New Drug Discovery
    • Current and Future Analysis
    • US and Europe Dominate, Asia-Pacific Lends Growth Momentum
    • Growth Momentum Shifts Away from In Vivo Technologies; In Vitro Technologies to Lead the Charge
    • Pharma Industry Renews Focus on Cost Optimization
    • China and India: Hot Spots for R&D Investment
    • ADME-Tox Assays - An Overview
    • Introduction of Early In Vitro ADMET Studies
    • Growing Prominence of Cell-based Assays in Drug Discovery and ADME Analysis
    • Major Types of Cell-Based HTS Assays for Drug Screening
    • CROs Expand Presence
    • Drug Discovery Outsourcing and Type of Services Outsourced
    • Changing Face of Drug Discovery Outsourcing Activity
    • M&A - Order of the Day
    • Impact of Covid-19 and a Looming Global Recession
  • 2. FOCUS ON SELECT PLAYERS
    • ACEA Biosciences, Inc. (USA)
    • ADMEcell, Inc. (USA)
    • Agilent Technologies, Inc. (USA)
    • Albany Molecular Research, Inc. (USA)
    • Beckman Coulter, Inc. (USA)
    • BioreclamationIVT, LLC (USA)
    • Cerep SA (France)
    • CompuDrug International, Inc. (USA)
    • Cyprotex PLC. (UK)
    • CeeTox, Inc. (USA)
    • Dassault Systemes Biovia Corp. (USA)
    • Eurofins ADME BIOANALYSES SAS (France)
    • Galapagos NV (Belgium)
    • Molecular Discovery Ltd. (UK)
    • MultiCASE, Inc. (USA)
    • Optivia Biotechnology (USA)
    • PerkinElmer, Inc. (USA)
    • Pharmaron, Inc. (USA)
    • Promega Corporation (USA)
    • Qualyst, Inc. (USA)
    • Simulations Plus, Inc. (USA)
    • Taconic Biosciences, Inc. (USA)
    • Takara Bio Europe AB (Sweden)
    • Tecan Group Ltd. (Switzerland)
    • Thermo Fisher Scientific, Inc. (USA)
  • 3. MARKET TRENDS & DRIVERS
    • Current State of ADME-Tox Testing
    • Need for Better Models: A Major Factor Driving Innovation in the Market
    • Focus Shifts to Innovative Approaches
    • In Silico and In Vitro- the Way to Go
    • In Vitro Testing Systems and Its Relevance in Drug Development
    • Growing Inclination towards In-vitro Assays for Toxicology Studies
    • In Silico ADME-Tox Growing at a Fast Clip
    • Advantages of Using In Silico Approaches
    • Factors Hindering Growth
    • 3-D Tissue Bioassays to Enhance In Vitro Toxicity Testing
    • Increasing Use of Cell-Based Assays over Other Methods in Toxicity Testing
    • Rising Number of Drug Targets Surge Demand for Cell-Based Assays
    • Growing Focus on the Development of Reproducible and Robust Cell-based Assays
    • Functional Assays: An Effective Way of Predicting Specific Toxic Effects
    • GPCR Targets to Drive Growth in Functional Cell Assay Market
    • New Alternatives for Early-Stage Toxicology Testing
    • Stem Cells Exude Great Potential in Drug Toxicity Testing
    • Primary Hepatocytes Become Standard Tool for Evaluation in Hepatic Metabolism
    • Improved Cryopreservation Technologies Help Expand Use of Hepatocytes
    • Cardiotoxicity Testing Gains Prominence
    • Cell Imaging-Gaining Popularity
    • In Vivo Imaging Persists in ADME-Tox Testing
    • Computational Models on Rise
    • Adoption of Data Management Systems
    • Drug Transporter Analysis Becoming Part of ADME Assessment
    • Slow Metabolism of Novel Drugs Call for More Human Models in Screening
    • Further Advances Required for More Understanding of Biotransformation
    • Introduction of Third Dimension in Cell Culturing Drives Need for New Instrumentation
    • Regulatory Bodies Focus on Transporter Mediated DDIs
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Current & Future Analysis for ADME-Toxicology Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 2: World Historic Review for ADME-Toxicology Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 3: World 15-Year Perspective for ADME-Toxicology Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2020 & 2027
    • TABLE 4: World Current & Future Analysis for Cell Culture by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 5: World Historic Review for Cell Culture by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 6: World 15-Year Perspective for Cell Culture by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 7: World Current & Future Analysis for High Throughput by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 8: World Historic Review for High Throughput by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 9: World 15-Year Perspective for High Throughput by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 10: World Current & Future Analysis for Molecular Imaging by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 11: World Historic Review for Molecular Imaging by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 12: World 15-Year Perspective for Molecular Imaging by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 13: World Current & Future Analysis for OMICS Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 14: World Historic Review for OMICS Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 15: World 15-Year Perspective for OMICS Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 16: World Current & Future Analysis for Cellular Assay by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 17: World Historic Review for Cellular Assay by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 18: World 15-Year Perspective for Cellular Assay by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 19: World Current & Future Analysis for Biochemical Assay by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 20: World Historic Review for Biochemical Assay by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 21: World 15-Year Perspective for Biochemical Assay by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 22: World Current & Future Analysis for Ex-vivo by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 23: World Historic Review for Ex-vivo by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 24: World 15-Year Perspective for Ex-vivo by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 25: World Current & Future Analysis for In Silica by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 26: World Historic Review for In Silica by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 27: World 15-Year Perspective for In Silica by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 28: World Current & Future Analysis for Systemic Toxicity by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 29: World Historic Review for Systemic Toxicity by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 30: World 15-Year Perspective for Systemic Toxicity by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 31: World Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 32: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 33: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

  • UNITED STATES
    • TABLE 34: USA Current & Future Analysis for ADME-Toxicology Testing by Technology - Cell Culture, High Throughput, Molecular Imaging and OMICS Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 35: USA Historic Review for ADME-Toxicology Testing by Technology - Cell Culture, High Throughput, Molecular Imaging and OMICS Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 36: USA 15-Year Perspective for ADME-Toxicology Testing by Technology - Percentage Breakdown of Value Sales for Cell Culture, High Throughput, Molecular Imaging and OMICS Technology for the Years 2012, 2020 & 2027
    • TABLE 37: USA Current & Future Analysis for ADME-Toxicology Testing by Method - Cellular Assay, Biochemical Assay, Ex-vivo and In Silica - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 38: USA Historic Review for ADME-Toxicology Testing by Method - Cellular Assay, Biochemical Assay, Ex-vivo and In Silica Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 39: USA 15-Year Perspective for ADME-Toxicology Testing by Method - Percentage Breakdown of Value Sales for Cellular Assay, Biochemical Assay, Ex-vivo and In Silica for the Years 2012, 2020 & 2027
    • TABLE 40: USA Current & Future Analysis for ADME-Toxicology Testing by Application - Systemic Toxicity and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 41: USA Historic Review for ADME-Toxicology Testing by Application - Systemic Toxicity and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 42: USA 15-Year Perspective for ADME-Toxicology Testing by Application - Percentage Breakdown of Value Sales for Systemic Toxicity and Other Applications for the Years 2012, 2020 & 2027
  • CANADA
    • TABLE 43: Canada Current & Future Analysis for ADME-Toxicology Testing by Technology - Cell Culture, High Throughput, Molecular Imaging and OMICS Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 44: Canada Historic Review for ADME-Toxicology Testing by Technology - Cell Culture, High Throughput, Molecular Imaging and OMICS Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 45: Canada 15-Year Perspective for ADME-Toxicology Testing by Technology - Percentage Breakdown of Value Sales for Cell Culture, High Throughput, Molecular Imaging and OMICS Technology for the Years 2012, 2020 & 2027
    • TABLE 46: Canada Current & Future Analysis for ADME-Toxicology Testing by Method - Cellular Assay, Biochemical Assay, Ex-vivo and In Silica - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 47: Canada Historic Review for ADME-Toxicology Testing by Method - Cellular Assay, Biochemical Assay, Ex-vivo and In Silica Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 48: Canada 15-Year Perspective for ADME-Toxicology Testing by Method - Percentage Breakdown of Value Sales for Cellular Assay, Biochemical Assay, Ex-vivo and In Silica for the Years 2012, 2020 & 2027
    • TABLE 49: Canada Current & Future Analysis for ADME-Toxicology Testing by Application - Systemic Toxicity and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 50: Canada Historic Review for ADME-Toxicology Testing by Application - Systemic Toxicity and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 51: Canada 15-Year Perspective for ADME-Toxicology Testing by Application - Percentage Breakdown of Value Sales for Systemic Toxicity and Other Applications for the Years 2012, 2020 & 2027
  • JAPAN
    • TABLE 52: Japan Current & Future Analysis for ADME-Toxicology Testing by Technology - Cell Culture, High Throughput, Molecular Imaging and OMICS Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 53: Japan Historic Review for ADME-Toxicology Testing by Technology - Cell Culture, High Throughput, Molecular Imaging and OMICS Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 54: Japan 15-Year Perspective for ADME-Toxicology Testing by Technology - Percentage Breakdown of Value Sales for Cell Culture, High Throughput, Molecular Imaging and OMICS Technology for the Years 2012, 2020 & 2027
    • TABLE 55: Japan Current & Future Analysis for ADME-Toxicology Testing by Method - Cellular Assay, Biochemical Assay, Ex-vivo and In Silica - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 56: Japan Historic Review for ADME-Toxicology Testing by Method - Cellular Assay, Biochemical Assay, Ex-vivo and In Silica Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 57: Japan 15-Year Perspective for ADME-Toxicology Testing by Method - Percentage Breakdown of Value Sales for Cellular Assay, Biochemical Assay, Ex-vivo and In Silica for the Years 2012, 2020 & 2027
    • TABLE 58: Japan Current & Future Analysis for ADME-Toxicology Testing by Application - Systemic Toxicity and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 59: Japan Historic Review for ADME-Toxicology Testing by Application - Systemic Toxicity and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 60: Japan 15-Year Perspective for ADME-Toxicology Testing by Application - Percentage Breakdown of Value Sales for Systemic Toxicity and Other Applications for the Years 2012, 2020 & 2027
  • CHINA
    • TABLE 61: China Current & Future Analysis for ADME-Toxicology Testing by Technology - Cell Culture, High Throughput, Molecular Imaging and OMICS Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 62: China Historic Review for ADME-Toxicology Testing by Technology - Cell Culture, High Throughput, Molecular Imaging and OMICS Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 63: China 15-Year Perspective for ADME-Toxicology Testing by Technology - Percentage Breakdown of Value Sales for Cell Culture, High Throughput, Molecular Imaging and OMICS Technology for the Years 2012, 2020 & 2027
    • TABLE 64: China Current & Future Analysis for ADME-Toxicology Testing by Method - Cellular Assay, Biochemical Assay, Ex-vivo and In Silica - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 65: China Historic Review for ADME-Toxicology Testing by Method - Cellular Assay, Biochemical Assay, Ex-vivo and In Silica Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 66: China 15-Year Perspective for ADME-Toxicology Testing by Method - Percentage Breakdown of Value Sales for Cellular Assay, Biochemical Assay, Ex-vivo and In Silica for the Years 2012, 2020 & 2027
    • TABLE 67: China Current & Future Analysis for ADME-Toxicology Testing by Application - Systemic Toxicity and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 68: China Historic Review for ADME-Toxicology Testing by Application - Systemic Toxicity and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 69: China 15-Year Perspective for ADME-Toxicology Testing by Application - Percentage Breakdown of Value Sales for Systemic Toxicity and Other Applications for the Years 2012, 2020 & 2027
  • EUROPE
    • TABLE 70: Europe Current & Future Analysis for ADME-Toxicology Testing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 71: Europe Historic Review for ADME-Toxicology Testing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 72: Europe 15-Year Perspective for ADME-Toxicology Testing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2020 & 2027
    • TABLE 73: Europe Current & Future Analysis for ADME-Toxicology Testing by Technology - Cell Culture, High Throughput, Molecular Imaging and OMICS Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 74: Europe Historic Review for ADME-Toxicology Testing by Technology - Cell Culture, High Throughput, Molecular Imaging and OMICS Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 75: Europe 15-Year Perspective for ADME-Toxicology Testing by Technology - Percentage Breakdown of Value Sales for Cell Culture, High Throughput, Molecular Imaging and OMICS Technology for the Years 2012, 2020 & 2027
    • TABLE 76: Europe Current & Future Analysis for ADME-Toxicology Testing by Method - Cellular Assay, Biochemical Assay, Ex-vivo and In Silica - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 77: Europe Historic Review for ADME-Toxicology Testing by Method - Cellular Assay, Biochemical Assay, Ex-vivo and In Silica Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 78: Europe 15-Year Perspective for ADME-Toxicology Testing by Method - Percentage Breakdown of Value Sales for Cellular Assay, Biochemical Assay, Ex-vivo and In Silica for the Years 2012, 2020 & 2027
    • TABLE 79: Europe Current & Future Analysis for ADME-Toxicology Testing by Application - Systemic Toxicity and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 80: Europe Historic Review for ADME-Toxicology Testing by Application - Systemic Toxicity and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 81: Europe 15-Year Perspective for ADME-Toxicology Testing by Application - Percentage Breakdown of Value Sales for Systemic Toxicity and Other Applications for the Years 2012, 2020 & 2027
  • FRANCE
    • TABLE 82: France Current & Future Analysis for ADME-Toxicology Testing by Technology - Cell Culture, High Throughput, Molecular Imaging and OMICS Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 83: France Historic Review for ADME-Toxicology Testing by Technology - Cell Culture, High Throughput, Molecular Imaging and OMICS Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 84: France 15-Year Perspective for ADME-Toxicology Testing by Technology - Percentage Breakdown of Value Sales for Cell Culture, High Throughput, Molecular Imaging and OMICS Technology for the Years 2012, 2020 & 2027
    • TABLE 85: France Current & Future Analysis for ADME-Toxicology Testing by Method - Cellular Assay, Biochemical Assay, Ex-vivo and In Silica - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 86: France Historic Review for ADME-Toxicology Testing by Method - Cellular Assay, Biochemical Assay, Ex-vivo and In Silica Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 87: France 15-Year Perspective for ADME-Toxicology Testing by Method - Percentage Breakdown of Value Sales for Cellular Assay, Biochemical Assay, Ex-vivo and In Silica for the Years 2012, 2020 & 2027
    • TABLE 88: France Current & Future Analysis for ADME-Toxicology Testing by Application - Systemic Toxicity and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 89: France Historic Review for ADME-Toxicology Testing by Application - Systemic Toxicity and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 90: France 15-Year Perspective for ADME-Toxicology Testing by Application - Percentage Breakdown of Value Sales for Systemic Toxicity and Other Applications for the Years 2012, 2020 & 2027
  • GERMANY
    • TABLE 91: Germany Current & Future Analysis for ADME-Toxicology Testing by Technology - Cell Culture, High Throughput, Molecular Imaging and OMICS Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 92: Germany Historic Review for ADME-Toxicology Testing by Technology - Cell Culture, High Throughput, Molecular Imaging and OMICS Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 93: Germany 15-Year Perspective for ADME-Toxicology Testing by Technology - Percentage Breakdown of Value Sales for Cell Culture, High Throughput, Molecular Imaging and OMICS Technology for the Years 2012, 2020 & 2027
    • TABLE 94: Germany Current & Future Analysis for ADME-Toxicology Testing by Method - Cellular Assay, Biochemical Assay, Ex-vivo and In Silica - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 95: Germany Historic Review for ADME-Toxicology Testing by Method - Cellular Assay, Biochemical Assay, Ex-vivo and In Silica Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 96: Germany 15-Year Perspective for ADME-Toxicology Testing by Method - Percentage Breakdown of Value Sales for Cellular Assay, Biochemical Assay, Ex-vivo and In Silica for the Years 2012, 2020 & 2027
    • TABLE 97: Germany Current & Future Analysis for ADME-Toxicology Testing by Application - Systemic Toxicity and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 98: Germany Historic Review for ADME-Toxicology Testing by Application - Systemic Toxicity and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 99: Germany 15-Year Perspective for ADME-Toxicology Testing by Application - Percentage Breakdown of Value Sales for Systemic Toxicity and Other Applications for the Years 2012, 2020 & 2027
  • ITALY
    • TABLE 100: Italy Current & Future Analysis for ADME-Toxicology Testing by Technology - Cell Culture, High Throughput, Molecular Imaging and OMICS Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 101: Italy Historic Review for ADME-Toxicology Testing by Technology - Cell Culture, High Throughput, Molecular Imaging and OMICS Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 102: Italy 15-Year Perspective for ADME-Toxicology Testing by Technology - Percentage Breakdown of Value Sales for Cell Culture, High Throughput, Molecular Imaging and OMICS Technology for the Years 2012, 2020 & 2027
    • TABLE 103: Italy Current & Future Analysis for ADME-Toxicology Testing by Method - Cellular Assay, Biochemical Assay, Ex-vivo and In Silica - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 104: Italy Historic Review for ADME-Toxicology Testing by Method - Cellular Assay, Biochemical Assay, Ex-vivo and In Silica Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 105: Italy 15-Year Perspective for ADME-Toxicology Testing by Method - Percentage Breakdown of Value Sales for Cellular Assay, Biochemical Assay, Ex-vivo and In Silica for the Years 2012, 2020 & 2027
    • TABLE 106: Italy Current & Future Analysis for ADME-Toxicology Testing by Application - Systemic Toxicity and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 107: Italy Historic Review for ADME-Toxicology Testing by Application - Systemic Toxicity and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 108: Italy 15-Year Perspective for ADME-Toxicology Testing by Application - Percentage Breakdown of Value Sales for Systemic Toxicity and Other Applications for the Years 2012, 2020 & 2027
  • UNITED KINGDOM
    • TABLE 109: UK Current & Future Analysis for ADME-Toxicology Testing by Technology - Cell Culture, High Throughput, Molecular Imaging and OMICS Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 110: UK Historic Review for ADME-Toxicology Testing by Technology - Cell Culture, High Throughput, Molecular Imaging and OMICS Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 111: UK 15-Year Perspective for ADME-Toxicology Testing by Technology - Percentage Breakdown of Value Sales for Cell Culture, High Throughput, Molecular Imaging and OMICS Technology for the Years 2012, 2020 & 2027
    • TABLE 112: UK Current & Future Analysis for ADME-Toxicology Testing by Method - Cellular Assay, Biochemical Assay, Ex-vivo and In Silica - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 113: UK Historic Review for ADME-Toxicology Testing by Method - Cellular Assay, Biochemical Assay, Ex-vivo and In Silica Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 114: UK 15-Year Perspective for ADME-Toxicology Testing by Method - Percentage Breakdown of Value Sales for Cellular Assay, Biochemical Assay, Ex-vivo and In Silica for the Years 2012, 2020 & 2027
    • TABLE 115: UK Current & Future Analysis for ADME-Toxicology Testing by Application - Systemic Toxicity and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 116: UK Historic Review for ADME-Toxicology Testing by Application - Systemic Toxicity and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 117: UK 15-Year Perspective for ADME-Toxicology Testing by Application - Percentage Breakdown of Value Sales for Systemic Toxicity and Other Applications for the Years 2012, 2020 & 2027
  • SPAIN
    • TABLE 118: Spain Current & Future Analysis for ADME-Toxicology Testing by Technology - Cell Culture, High Throughput, Molecular Imaging and OMICS Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 119: Spain Historic Review for ADME-Toxicology Testing by Technology - Cell Culture, High Throughput, Molecular Imaging and OMICS Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 120: Spain 15-Year Perspective for ADME-Toxicology Testing by Technology - Percentage Breakdown of Value Sales for Cell Culture, High Throughput, Molecular Imaging and OMICS Technology for the Years 2012, 2020 & 2027
    • TABLE 121: Spain Current & Future Analysis for ADME-Toxicology Testing by Method - Cellular Assay, Biochemical Assay, Ex-vivo and In Silica - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 122: Spain Historic Review for ADME-Toxicology Testing by Method - Cellular Assay, Biochemical Assay, Ex-vivo and In Silica Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 123: Spain 15-Year Perspective for ADME-Toxicology Testing by Method - Percentage Breakdown of Value Sales for Cellular Assay, Biochemical Assay, Ex-vivo and In Silica for the Years 2012, 2020 & 2027
    • TABLE 124: Spain Current & Future Analysis for ADME-Toxicology Testing by Application - Systemic Toxicity and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 125: Spain Historic Review for ADME-Toxicology Testing by Application - Systemic Toxicity and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 126: Spain 15-Year Perspective for ADME-Toxicology Testing by Application - Percentage Breakdown of Value Sales for Systemic Toxicity and Other Applications for the Years 2012, 2020 & 2027
  • RUSSIA
    • TABLE 127: Russia Current & Future Analysis for ADME-Toxicology Testing by Technology - Cell Culture, High Throughput, Molecular Imaging and OMICS Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 128: Russia Historic Review for ADME-Toxicology Testing by Technology - Cell Culture, High Throughput, Molecular Imaging and OMICS Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 129: Russia 15-Year Perspective for ADME-Toxicology Testing by Technology - Percentage Breakdown of Value Sales for Cell Culture, High Throughput, Molecular Imaging and OMICS Technology for the Years 2012, 2020 & 2027
    • TABLE 130: Russia Current & Future Analysis for ADME-Toxicology Testing by Method - Cellular Assay, Biochemical Assay, Ex-vivo and In Silica - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 131: Russia Historic Review for ADME-Toxicology Testing by Method - Cellular Assay, Biochemical Assay, Ex-vivo and In Silica Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 132: Russia 15-Year Perspective for ADME-Toxicology Testing by Method - Percentage Breakdown of Value Sales for Cellular Assay, Biochemical Assay, Ex-vivo and In Silica for the Years 2012, 2020 & 2027
    • TABLE 133: Russia Current & Future Analysis for ADME-Toxicology Testing by Application - Systemic Toxicity and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 134: Russia Historic Review for ADME-Toxicology Testing by Application - Systemic Toxicity and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 135: Russia 15-Year Perspective for ADME-Toxicology Testing by Application - Percentage Breakdown of Value Sales for Systemic Toxicity and Other Applications for the Years 2012, 2020 & 2027
  • REST OF EUROPE
    • TABLE 136: Rest of Europe Current & Future Analysis for ADME-Toxicology Testing by Technology - Cell Culture, High Throughput, Molecular Imaging and OMICS Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 137: Rest of Europe Historic Review for ADME-Toxicology Testing by Technology - Cell Culture, High Throughput, Molecular Imaging and OMICS Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 138: Rest of Europe 15-Year Perspective for ADME-Toxicology Testing by Technology - Percentage Breakdown of Value Sales for Cell Culture, High Throughput, Molecular Imaging and OMICS Technology for the Years 2012, 2020 & 2027
    • TABLE 139: Rest of Europe Current & Future Analysis for ADME-Toxicology Testing by Method - Cellular Assay, Biochemical Assay, Ex-vivo and In Silica - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 140: Rest of Europe Historic Review for ADME-Toxicology Testing by Method - Cellular Assay, Biochemical Assay, Ex-vivo and In Silica Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 141: Rest of Europe 15-Year Perspective for ADME-Toxicology Testing by Method - Percentage Breakdown of Value Sales for Cellular Assay, Biochemical Assay, Ex-vivo and In Silica for the Years 2012, 2020 & 2027
    • TABLE 142: Rest of Europe Current & Future Analysis for ADME-Toxicology Testing by Application - Systemic Toxicity and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 143: Rest of Europe Historic Review for ADME-Toxicology Testing by Application - Systemic Toxicity and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 144: Rest of Europe 15-Year Perspective for ADME-Toxicology Testing by Application - Percentage Breakdown of Value Sales for Systemic Toxicity and Other Applications for the Years 2012, 2020 & 2027
  • ASIA-PACIFIC
    • TABLE 145: Asia-Pacific Current & Future Analysis for ADME-Toxicology Testing by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 146: Asia-Pacific Historic Review for ADME-Toxicology Testing by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 147: Asia-Pacific 15-Year Perspective for ADME-Toxicology Testing by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2012, 2020 & 2027
    • TABLE 148: Asia-Pacific Current & Future Analysis for ADME-Toxicology Testing by Technology - Cell Culture, High Throughput, Molecular Imaging and OMICS Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 149: Asia-Pacific Historic Review for ADME-Toxicology Testing by Technology - Cell Culture, High Throughput, Molecular Imaging and OMICS Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 150: Asia-Pacific 15-Year Perspective for ADME-Toxicology Testing by Technology - Percentage Breakdown of Value Sales for Cell Culture, High Throughput, Molecular Imaging and OMICS Technology for the Years 2012, 2020 & 2027
    • TABLE 151: Asia-Pacific Current & Future Analysis for ADME-Toxicology Testing by Method - Cellular Assay, Biochemical Assay, Ex-vivo and In Silica - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 152: Asia-Pacific Historic Review for ADME-Toxicology Testing by Method - Cellular Assay, Biochemical Assay, Ex-vivo and In Silica Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 153: Asia-Pacific 15-Year Perspective for ADME-Toxicology Testing by Method - Percentage Breakdown of Value Sales for Cellular Assay, Biochemical Assay, Ex-vivo and In Silica for the Years 2012, 2020 & 2027
    • TABLE 154: Asia-Pacific Current & Future Analysis for ADME-Toxicology Testing by Application - Systemic Toxicity and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 155: Asia-Pacific Historic Review for ADME-Toxicology Testing by Application - Systemic Toxicity and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 156: Asia-Pacific 15-Year Perspective for ADME-Toxicology Testing by Application - Percentage Breakdown of Value Sales for Systemic Toxicity and Other Applications for the Years 2012, 2020 & 2027
  • AUSTRALIA
    • TABLE 157: Australia Current & Future Analysis for ADME-Toxicology Testing by Technology - Cell Culture, High Throughput, Molecular Imaging and OMICS Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 158: Australia Historic Review for ADME-Toxicology Testing by Technology - Cell Culture, High Throughput, Molecular Imaging and OMICS Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 159: Australia 15-Year Perspective for ADME-Toxicology Testing by Technology - Percentage Breakdown of Value Sales for Cell Culture, High Throughput, Molecular Imaging and OMICS Technology for the Years 2012, 2020 & 2027
    • TABLE 160: Australia Current & Future Analysis for ADME-Toxicology Testing by Method - Cellular Assay, Biochemical Assay, Ex-vivo and In Silica - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 161: Australia Historic Review for ADME-Toxicology Testing by Method - Cellular Assay, Biochemical Assay, Ex-vivo and In Silica Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 162: Australia 15-Year Perspective for ADME-Toxicology Testing by Method - Percentage Breakdown of Value Sales for Cellular Assay, Biochemical Assay, Ex-vivo and In Silica for the Years 2012, 2020 & 2027
    • TABLE 163: Australia Current & Future Analysis for ADME-Toxicology Testing by Application - Systemic Toxicity and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 164: Australia Historic Review for ADME-Toxicology Testing by Application - Systemic Toxicity and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 165: Australia 15-Year Perspective for ADME-Toxicology Testing by Application - Percentage Breakdown of Value Sales for Systemic Toxicity and Other Applications for the Years 2012, 2020 & 2027
  • INDIA
    • TABLE 166: India Current & Future Analysis for ADME-Toxicology Testing by Technology - Cell Culture, High Throughput, Molecular Imaging and OMICS Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 167: India Historic Review for ADME-Toxicology Testing by Technology - Cell Culture, High Throughput, Molecular Imaging and OMICS Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 168: India 15-Year Perspective for ADME-Toxicology Testing by Technology - Percentage Breakdown of Value Sales for Cell Culture, High Throughput, Molecular Imaging and OMICS Technology for the Years 2012, 2020 & 2027
    • TABLE 169: India Current & Future Analysis for ADME-Toxicology Testing by Method - Cellular Assay, Biochemical Assay, Ex-vivo and In Silica - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 170: India Historic Review for ADME-Toxicology Testing by Method - Cellular Assay, Biochemical Assay, Ex-vivo and In Silica Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 171: India 15-Year Perspective for ADME-Toxicology Testing by Method - Percentage Breakdown of Value Sales for Cellular Assay, Biochemical Assay, Ex-vivo and In Silica for the Years 2012, 2020 & 2027
    • TABLE 172: India Current & Future Analysis for ADME-Toxicology Testing by Application - Systemic Toxicity and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 173: India Historic Review for ADME-Toxicology Testing by Application - Systemic Toxicity and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 174: India 15-Year Perspective for ADME-Toxicology Testing by Application - Percentage Breakdown of Value Sales for Systemic Toxicity and Other Applications for the Years 2012, 2020 & 2027
  • SOUTH KOREA
    • TABLE 175: South Korea Current & Future Analysis for ADME-Toxicology Testing by Technology - Cell Culture, High Throughput, Molecular Imaging and OMICS Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 176: South Korea Historic Review for ADME-Toxicology Testing by Technology - Cell Culture, High Throughput, Molecular Imaging and OMICS Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 177: South Korea 15-Year Perspective for ADME-Toxicology Testing by Technology - Percentage Breakdown of Value Sales for Cell Culture, High Throughput, Molecular Imaging and OMICS Technology for the Years 2012, 2020 & 2027
    • TABLE 178: South Korea Current & Future Analysis for ADME-Toxicology Testing by Method - Cellular Assay, Biochemical Assay, Ex-vivo and In Silica - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 179: South Korea Historic Review for ADME-Toxicology Testing by Method - Cellular Assay, Biochemical Assay, Ex-vivo and In Silica Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 180: South Korea 15-Year Perspective for ADME-Toxicology Testing by Method - Percentage Breakdown of Value Sales for Cellular Assay, Biochemical Assay, Ex-vivo and In Silica for the Years 2012, 2020 & 2027
    • TABLE 181: South Korea Current & Future Analysis for ADME-Toxicology Testing by Application - Systemic Toxicity and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 182: South Korea Historic Review for ADME-Toxicology Testing by Application - Systemic Toxicity and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 183: South Korea 15-Year Perspective for ADME-Toxicology Testing by Application - Percentage Breakdown of Value Sales for Systemic Toxicity and Other Applications for the Years 2012, 2020 & 2027
  • REST OF ASIA-PACIFIC
    • TABLE 184: Rest of Asia-Pacific Current & Future Analysis for ADME-Toxicology Testing by Technology - Cell Culture, High Throughput, Molecular Imaging and OMICS Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 185: Rest of Asia-Pacific Historic Review for ADME-Toxicology Testing by Technology - Cell Culture, High Throughput, Molecular Imaging and OMICS Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 186: Rest of Asia-Pacific 15-Year Perspective for ADME-Toxicology Testing by Technology - Percentage Breakdown of Value Sales for Cell Culture, High Throughput, Molecular Imaging and OMICS Technology for the Years 2012, 2020 & 2027
    • TABLE 187: Rest of Asia-Pacific Current & Future Analysis for ADME-Toxicology Testing by Method - Cellular Assay, Biochemical Assay, Ex-vivo and In Silica - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 188: Rest of Asia-Pacific Historic Review for ADME-Toxicology Testing by Method - Cellular Assay, Biochemical Assay, Ex-vivo and In Silica Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 189: Rest of Asia-Pacific 15-Year Perspective for ADME-Toxicology Testing by Method - Percentage Breakdown of Value Sales for Cellular Assay, Biochemical Assay, Ex-vivo and In Silica for the Years 2012, 2020 & 2027
    • TABLE 190: Rest of Asia-Pacific Current & Future Analysis for ADME-Toxicology Testing by Application - Systemic Toxicity and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 191: Rest of Asia-Pacific Historic Review for ADME-Toxicology Testing by Application - Systemic Toxicity and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 192: Rest of Asia-Pacific 15-Year Perspective for ADME-Toxicology Testing by Application - Percentage Breakdown of Value Sales for Systemic Toxicity and Other Applications for the Years 2012, 2020 & 2027
  • LATIN AMERICA
    • TABLE 193: Latin America Current & Future Analysis for ADME-Toxicology Testing by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 194: Latin America Historic Review for ADME-Toxicology Testing by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 195: Latin America 15-Year Perspective for ADME-Toxicology Testing by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2012, 2020 & 2027
    • TABLE 196: Latin America Current & Future Analysis for ADME-Toxicology Testing by Technology - Cell Culture, High Throughput, Molecular Imaging and OMICS Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 197: Latin America Historic Review for ADME-Toxicology Testing by Technology - Cell Culture, High Throughput, Molecular Imaging and OMICS Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 198: Latin America 15-Year Perspective for ADME-Toxicology Testing by Technology - Percentage Breakdown of Value Sales for Cell Culture, High Throughput, Molecular Imaging and OMICS Technology for the Years 2012, 2020 & 2027
    • TABLE 199: Latin America Current & Future Analysis for ADME-Toxicology Testing by Method - Cellular Assay, Biochemical Assay, Ex-vivo and In Silica - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 200: Latin America Historic Review for ADME-Toxicology Testing by Method - Cellular Assay, Biochemical Assay, Ex-vivo and In Silica Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 201: Latin America 15-Year Perspective for ADME-Toxicology Testing by Method - Percentage Breakdown of Value Sales for Cellular Assay, Biochemical Assay, Ex-vivo and In Silica for the Years 2012, 2020 & 2027
    • TABLE 202: Latin America Current & Future Analysis for ADME-Toxicology Testing by Application - Systemic Toxicity and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 203: Latin America Historic Review for ADME-Toxicology Testing by Application - Systemic Toxicity and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 204: Latin America 15-Year Perspective for ADME-Toxicology Testing by Application - Percentage Breakdown of Value Sales for Systemic Toxicity and Other Applications for the Years 2012, 2020 & 2027
  • ARGENTINA
    • TABLE 205: Argentina Current & Future Analysis for ADME-Toxicology Testing by Technology - Cell Culture, High Throughput, Molecular Imaging and OMICS Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 206: Argentina Historic Review for ADME-Toxicology Testing by Technology - Cell Culture, High Throughput, Molecular Imaging and OMICS Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 207: Argentina 15-Year Perspective for ADME-Toxicology Testing by Technology - Percentage Breakdown of Value Sales for Cell Culture, High Throughput, Molecular Imaging and OMICS Technology for the Years 2012, 2020 & 2027
    • TABLE 208: Argentina Current & Future Analysis for ADME-Toxicology Testing by Method - Cellular Assay, Biochemical Assay, Ex-vivo and In Silica - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 209: Argentina Historic Review for ADME-Toxicology Testing by Method - Cellular Assay, Biochemical Assay, Ex-vivo and In Silica Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 210: Argentina 15-Year Perspective for ADME-Toxicology Testing by Method - Percentage Breakdown of Value Sales for Cellular Assay, Biochemical Assay, Ex-vivo and In Silica for the Years 2012, 2020 & 2027
    • TABLE 211: Argentina Current & Future Analysis for ADME-Toxicology Testing by Application - Systemic Toxicity and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 212: Argentina Historic Review for ADME-Toxicology Testing by Application - Systemic Toxicity and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 213: Argentina 15-Year Perspective for ADME-Toxicology Testing by Application - Percentage Breakdown of Value Sales for Systemic Toxicity and Other Applications for the Years 2012, 2020 & 2027
  • BRAZIL
    • TABLE 214: Brazil Current & Future Analysis for ADME-Toxicology Testing by Technology - Cell Culture, High Throughput, Molecular Imaging and OMICS Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 215: Brazil Historic Review for ADME-Toxicology Testing by Technology - Cell Culture, High Throughput, Molecular Imaging and OMICS Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 216: Brazil 15-Year Perspective for ADME-Toxicology Testing by Technology - Percentage Breakdown of Value Sales for Cell Culture, High Throughput, Molecular Imaging and OMICS Technology for the Years 2012, 2020 & 2027
    • TABLE 217: Brazil Current & Future Analysis for ADME-Toxicology Testing by Method - Cellular Assay, Biochemical Assay, Ex-vivo and In Silica - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 218: Brazil Historic Review for ADME-Toxicology Testing by Method - Cellular Assay, Biochemical Assay, Ex-vivo and In Silica Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 219: Brazil 15-Year Perspective for ADME-Toxicology Testing by Method - Percentage Breakdown of Value Sales for Cellular Assay, Biochemical Assay, Ex-vivo and In Silica for the Years 2012, 2020 & 2027
    • TABLE 220: Brazil Current & Future Analysis for ADME-Toxicology Testing by Application - Systemic Toxicity and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 221: Brazil Historic Review for ADME-Toxicology Testing by Application - Systemic Toxicity and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 222: Brazil 15-Year Perspective for ADME-Toxicology Testing by Application - Percentage Breakdown of Value Sales for Systemic Toxicity and Other Applications for the Years 2012, 2020 & 2027
  • MEXICO
    • TABLE 223: Mexico Current & Future Analysis for ADME-Toxicology Testing by Technology - Cell Culture, High Throughput, Molecular Imaging and OMICS Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 224: Mexico Historic Review for ADME-Toxicology Testing by Technology - Cell Culture, High Throughput, Molecular Imaging and OMICS Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 225: Mexico 15-Year Perspective for ADME-Toxicology Testing by Technology - Percentage Breakdown of Value Sales for Cell Culture, High Throughput, Molecular Imaging and OMICS Technology for the Years 2012, 2020 & 2027
    • TABLE 226: Mexico Current & Future Analysis for ADME-Toxicology Testing by Method - Cellular Assay, Biochemical Assay, Ex-vivo and In Silica - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 227: Mexico Historic Review for ADME-Toxicology Testing by Method - Cellular Assay, Biochemical Assay, Ex-vivo and In Silica Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 228: Mexico 15-Year Perspective for ADME-Toxicology Testing by Method - Percentage Breakdown of Value Sales for Cellular Assay, Biochemical Assay, Ex-vivo and In Silica for the Years 2012, 2020 & 2027
    • TABLE 229: Mexico Current & Future Analysis for ADME-Toxicology Testing by Application - Systemic Toxicity and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 230: Mexico Historic Review for ADME-Toxicology Testing by Application - Systemic Toxicity and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 231: Mexico 15-Year Perspective for ADME-Toxicology Testing by Application - Percentage Breakdown of Value Sales for Systemic Toxicity and Other Applications for the Years 2012, 2020 & 2027
  • REST OF LATIN AMERICA
    • TABLE 232: Rest of Latin America Current & Future Analysis for ADME-Toxicology Testing by Technology - Cell Culture, High Throughput, Molecular Imaging and OMICS Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 233: Rest of Latin America Historic Review for ADME-Toxicology Testing by Technology - Cell Culture, High Throughput, Molecular Imaging and OMICS Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 234: Rest of Latin America 15-Year Perspective for ADME-Toxicology Testing by Technology - Percentage Breakdown of Value Sales for Cell Culture, High Throughput, Molecular Imaging and OMICS Technology for the Years 2012, 2020 & 2027
    • TABLE 235: Rest of Latin America Current & Future Analysis for ADME-Toxicology Testing by Method - Cellular Assay, Biochemical Assay, Ex-vivo and In Silica - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 236: Rest of Latin America Historic Review for ADME-Toxicology Testing by Method - Cellular Assay, Biochemical Assay, Ex-vivo and In Silica Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 237: Rest of Latin America 15-Year Perspective for ADME-Toxicology Testing by Method - Percentage Breakdown of Value Sales for Cellular Assay, Biochemical Assay, Ex-vivo and In Silica for the Years 2012, 2020 & 2027
    • TABLE 238: Rest of Latin America Current & Future Analysis for ADME-Toxicology Testing by Application - Systemic Toxicity and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 239: Rest of Latin America Historic Review for ADME-Toxicology Testing by Application - Systemic Toxicity and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 240: Rest of Latin America 15-Year Perspective for ADME-Toxicology Testing by Application - Percentage Breakdown of Value Sales for Systemic Toxicity and Other Applications for the Years 2012, 2020 & 2027
  • MIDDLE EAST
    • TABLE 241: Middle East Current & Future Analysis for ADME-Toxicology Testing by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 242: Middle East Historic Review for ADME-Toxicology Testing by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 243: Middle East 15-Year Perspective for ADME-Toxicology Testing by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2012, 2020 & 2027
    • TABLE 244: Middle East Current & Future Analysis for ADME-Toxicology Testing by Technology - Cell Culture, High Throughput, Molecular Imaging and OMICS Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 245: Middle East Historic Review for ADME-Toxicology Testing by Technology - Cell Culture, High Throughput, Molecular Imaging and OMICS Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 246: Middle East 15-Year Perspective for ADME-Toxicology Testing by Technology - Percentage Breakdown of Value Sales for Cell Culture, High Throughput, Molecular Imaging and OMICS Technology for the Years 2012, 2020 & 2027
    • TABLE 247: Middle East Current & Future Analysis for ADME-Toxicology Testing by Method - Cellular Assay, Biochemical Assay, Ex-vivo and In Silica - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 248: Middle East Historic Review for ADME-Toxicology Testing by Method - Cellular Assay, Biochemical Assay, Ex-vivo and In Silica Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 249: Middle East 15-Year Perspective for ADME-Toxicology Testing by Method - Percentage Breakdown of Value Sales for Cellular Assay, Biochemical Assay, Ex-vivo and In Silica for the Years 2012, 2020 & 2027
    • TABLE 250: Middle East Current & Future Analysis for ADME-Toxicology Testing by Application - Systemic Toxicity and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 251: Middle East Historic Review for ADME-Toxicology Testing by Application - Systemic Toxicity and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 252: Middle East 15-Year Perspective for ADME-Toxicology Testing by Application - Percentage Breakdown of Value Sales for Systemic Toxicity and Other Applications for the Years 2012, 2020 & 2027
  • IRAN
    • TABLE 253: Iran Current & Future Analysis for ADME-Toxicology Testing by Technology - Cell Culture, High Throughput, Molecular Imaging and OMICS Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 254: Iran Historic Review for ADME-Toxicology Testing by Technology - Cell Culture, High Throughput, Molecular Imaging and OMICS Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 255: Iran 15-Year Perspective for ADME-Toxicology Testing by Technology - Percentage Breakdown of Value Sales for Cell Culture, High Throughput, Molecular Imaging and OMICS Technology for the Years 2012, 2020 & 2027
    • TABLE 256: Iran Current & Future Analysis for ADME-Toxicology Testing by Method - Cellular Assay, Biochemical Assay, Ex-vivo and In Silica - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 257: Iran Historic Review for ADME-Toxicology Testing by Method - Cellular Assay, Biochemical Assay, Ex-vivo and In Silica Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 258: Iran 15-Year Perspective for ADME-Toxicology Testing by Method - Percentage Breakdown of Value Sales for Cellular Assay, Biochemical Assay, Ex-vivo and In Silica for the Years 2012, 2020 & 2027
    • TABLE 259: Iran Current & Future Analysis for ADME-Toxicology Testing by Application - Systemic Toxicity and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 260: Iran Historic Review for ADME-Toxicology Testing by Application - Systemic Toxicity and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 261: Iran 15-Year Perspective for ADME-Toxicology Testing by Application - Percentage Breakdown of Value Sales for Systemic Toxicity and Other Applications for the Years 2012, 2020 & 2027
  • ISRAEL
    • TABLE 262: Israel Current & Future Analysis for ADME-Toxicology Testing by Technology - Cell Culture, High Throughput, Molecular Imaging and OMICS Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 263: Israel Historic Review for ADME-Toxicology Testing by Technology - Cell Culture, High Throughput, Molecular Imaging and OMICS Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 264: Israel 15-Year Perspective for ADME-Toxicology Testing by Technology - Percentage Breakdown of Value Sales for Cell Culture, High Throughput, Molecular Imaging and OMICS Technology for the Years 2012, 2020 & 2027
    • TABLE 265: Israel Current & Future Analysis for ADME-Toxicology Testing by Method - Cellular Assay, Biochemical Assay, Ex-vivo and In Silica - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 266: Israel Historic Review for ADME-Toxicology Testing by Method - Cellular Assay, Biochemical Assay, Ex-vivo and In Silica Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 267: Israel 15-Year Perspective for ADME-Toxicology Testing by Method - Percentage Breakdown of Value Sales for Cellular Assay, Biochemical Assay, Ex-vivo and In Silica for the Years 2012, 2020 & 2027
    • TABLE 268: Israel Current & Future Analysis for ADME-Toxicology Testing by Application - Systemic Toxicity and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 269: Israel Historic Review for ADME-Toxicology Testing by Application - Systemic Toxicity and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 270: Israel 15-Year Perspective for ADME-Toxicology Testing by Application - Percentage Breakdown of Value Sales for Systemic Toxicity and Other Applications for the Years 2012, 2020 & 2027
  • SAUDI ARABIA
    • TABLE 271: Saudi Arabia Current & Future Analysis for ADME-Toxicology Testing by Technology - Cell Culture, High Throughput, Molecular Imaging and OMICS Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 272: Saudi Arabia Historic Review for ADME-Toxicology Testing by Technology - Cell Culture, High Throughput, Molecular Imaging and OMICS Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 273: Saudi Arabia 15-Year Perspective for ADME-Toxicology Testing by Technology - Percentage Breakdown of Value Sales for Cell Culture, High Throughput, Molecular Imaging and OMICS Technology for the Years 2012, 2020 & 2027
    • TABLE 274: Saudi Arabia Current & Future Analysis for ADME-Toxicology Testing by Method - Cellular Assay, Biochemical Assay, Ex-vivo and In Silica - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 275: Saudi Arabia Historic Review for ADME-Toxicology Testing by Method - Cellular Assay, Biochemical Assay, Ex-vivo and In Silica Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 276: Saudi Arabia 15-Year Perspective for ADME-Toxicology Testing by Method - Percentage Breakdown of Value Sales for Cellular Assay, Biochemical Assay, Ex-vivo and In Silica for the Years 2012, 2020 & 2027
    • TABLE 277: Saudi Arabia Current & Future Analysis for ADME-Toxicology Testing by Application - Systemic Toxicity and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 278: Saudi Arabia Historic Review for ADME-Toxicology Testing by Application - Systemic Toxicity and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 279: Saudi Arabia 15-Year Perspective for ADME-Toxicology Testing by Application - Percentage Breakdown of Value Sales for Systemic Toxicity and Other Applications for the Years 2012, 2020 & 2027
  • UNITED ARAB EMIRATES
    • TABLE 280: UAE Current & Future Analysis for ADME-Toxicology Testing by Technology - Cell Culture, High Throughput, Molecular Imaging and OMICS Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 281: UAE Historic Review for ADME-Toxicology Testing by Technology - Cell Culture, High Throughput, Molecular Imaging and OMICS Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 282: UAE 15-Year Perspective for ADME-Toxicology Testing by Technology - Percentage Breakdown of Value Sales for Cell Culture, High Throughput, Molecular Imaging and OMICS Technology for the Years 2012, 2020 & 2027
    • TABLE 283: UAE Current & Future Analysis for ADME-Toxicology Testing by Method - Cellular Assay, Biochemical Assay, Ex-vivo and In Silica - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 284: UAE Historic Review for ADME-Toxicology Testing by Method - Cellular Assay, Biochemical Assay, Ex-vivo and In Silica Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 285: UAE 15-Year Perspective for ADME-Toxicology Testing by Method - Percentage Breakdown of Value Sales for Cellular Assay, Biochemical Assay, Ex-vivo and In Silica for the Years 2012, 2020 & 2027
    • TABLE 286: UAE Current & Future Analysis for ADME-Toxicology Testing by Application - Systemic Toxicity and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 287: UAE Historic Review for ADME-Toxicology Testing by Application - Systemic Toxicity and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 288: UAE 15-Year Perspective for ADME-Toxicology Testing by Application - Percentage Breakdown of Value Sales for Systemic Toxicity and Other Applications for the Years 2012, 2020 & 2027
  • REST OF MIDDLE EAST
    • TABLE 289: Rest of Middle East Current & Future Analysis for ADME-Toxicology Testing by Technology - Cell Culture, High Throughput, Molecular Imaging and OMICS Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 290: Rest of Middle East Historic Review for ADME-Toxicology Testing by Technology - Cell Culture, High Throughput, Molecular Imaging and OMICS Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 291: Rest of Middle East 15-Year Perspective for ADME-Toxicology Testing by Technology - Percentage Breakdown of Value Sales for Cell Culture, High Throughput, Molecular Imaging and OMICS Technology for the Years 2012, 2020 & 2027
    • TABLE 292: Rest of Middle East Current & Future Analysis for ADME-Toxicology Testing by Method - Cellular Assay, Biochemical Assay, Ex-vivo and In Silica - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 293: Rest of Middle East Historic Review for ADME-Toxicology Testing by Method - Cellular Assay, Biochemical Assay, Ex-vivo and In Silica Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 294: Rest of Middle East 15-Year Perspective for ADME-Toxicology Testing by Method - Percentage Breakdown of Value Sales for Cellular Assay, Biochemical Assay, Ex-vivo and In Silica for the Years 2012, 2020 & 2027
    • TABLE 295: Rest of Middle East Current & Future Analysis for ADME-Toxicology Testing by Application - Systemic Toxicity and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 296: Rest of Middle East Historic Review for ADME-Toxicology Testing by Application - Systemic Toxicity and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 297: Rest of Middle East 15-Year Perspective for ADME-Toxicology Testing by Application - Percentage Breakdown of Value Sales for Systemic Toxicity and Other Applications for the Years 2012, 2020 & 2027
  • AFRICA
    • TABLE 298: Africa Current & Future Analysis for ADME-Toxicology Testing by Technology - Cell Culture, High Throughput, Molecular Imaging and OMICS Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 299: Africa Historic Review for ADME-Toxicology Testing by Technology - Cell Culture, High Throughput, Molecular Imaging and OMICS Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 300: Africa 15-Year Perspective for ADME-Toxicology Testing by Technology - Percentage Breakdown of Value Sales for Cell Culture, High Throughput, Molecular Imaging and OMICS Technology for the Years 2012, 2020 & 2027
    • TABLE 301: Africa Current & Future Analysis for ADME-Toxicology Testing by Method - Cellular Assay, Biochemical Assay, Ex-vivo and In Silica - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 302: Africa Historic Review for ADME-Toxicology Testing by Method - Cellular Assay, Biochemical Assay, Ex-vivo and In Silica Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 303: Africa 15-Year Perspective for ADME-Toxicology Testing by Method - Percentage Breakdown of Value Sales for Cellular Assay, Biochemical Assay, Ex-vivo and In Silica for the Years 2012, 2020 & 2027
    • TABLE 304: Africa Current & Future Analysis for ADME-Toxicology Testing by Application - Systemic Toxicity and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 305: Africa Historic Review for ADME-Toxicology Testing by Application - Systemic Toxicity and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 306: Africa 15-Year Perspective for ADME-Toxicology Testing by Application - Percentage Breakdown of Value Sales for Systemic Toxicity and Other Applications for the Years 2012, 2020 & 2027

IV. COMPETITION

  • Total Companies Profiled: 69